Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
复制标题
DOI：
--
复制
发表时间：
2014-08
影响因子：
2
通讯作者：
S. Nam;Fusanori Yotsumoto;Kohei Miyata;Y. Suzaki;H. Yagi;T. Odawara;S. Manabe;Toyokazu Ishikawa;M. Kuroki;E. Mekada;S. Miyamoto
中科院分区：
文献类型：
--
作者：
S. Nam;Fusanori Yotsumoto;Kohei Miyata;Y. Suzaki;H. Yagi;T. Odawara;S. Manabe;Toyokazu Ishikawa;M. Kuroki;E. Mekada;S. Miyamoto
背景/目的肝素结合表皮生长因子样生长因子（HB-EGF）是表皮生长因子家族的成员，是卵巢癌治疗的靶点。本研究调查了 BK-UM（一种针对 HB-EGF 的抗癌药物）的给药方案。材料和方法 将卵巢癌细胞系 RMG-I 皮下注射到五周大的雌性裸鼠体内。 BK-UM 采用腹腔内给药，采用三种不同剂量的给药方案。每周计算肿瘤体积。使用曼-惠特尼 U 检验评估统计显着性。结果 当剂量 >0.1 mg/kg 时，BK-UM 显示出显着的抗肿瘤作用，尽管小鼠的抗肿瘤作用和体重因剂量或三种不同的给药方案而没有显着差异。然而，在<0.1 mg/kg的剂量下，BK-UM对肿瘤生长几乎没有抑制作用。结论 每日服用 BK-UM 具有潜在的剂量依赖性抗肿瘤作用，可能是临床应用的最佳方案。
BACKGROUND/AIM Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family, is a target for ovarian cancer therapy. The present study investigated the administration schedule of BK-UM, an anticancer agent targeting HB-EGF. MATERIALS AND METHODS The ovarian cancer cell line, RMG-I, was injected subcutaneously into five-week-old female nude mice. The BK-UM was administered intraperitoneally, using three administration schedules with different doses. The tumor volume was calculated every week. Statistical significance was assessed using the Mann-Whitney U-test. RESULTS At doses >0.1 mg/kg, BK-UM displayed significant antitumor effects, although the antitumor effects and body weights of mice did not significantly differ by dose or by three different administration schedules. At a dose <0.1 mg/kg, however, BK-UM had little inhibitory effect on tumor growth. CONCLUSION Daily administration of BK-UM, which has a potentially dose-dependent antitumor effect, may be the optimal schedule for clinical application.